慢性髓性白血病和T315IBCR::ABL1突变
Federico Pierro1, Stefania Stella2, Manlio Fazio1
1Division of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, Via Consolare Valeria, 98125 Messina, Italy.
International journal of molecular sciences
|December 11, 2025
概括
慢性髓性白血病 (CML) 中的T315I突变会导致对标准氨酸激酶抑制剂 (TKI) 的耐药性. 新的治疗策略,包括第三代技术知识,对于管理这种具有挑战性的突变至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性骨髓性白血病 (CML) 是一种由费城染色体和BCR::ABL1coprotein定义的骨髓扩散性瘤.
- 氨酸激酶抑制剂 (TKI) 从2001年开始彻底改变了CML治疗.
- 获得对TKI的耐药性,通常是由于T315I等突变,仍然是一个重要的临床挑战.
研究的目的:
- 审查关于CML中T315I突变的当前知识.
- 探索T315I突变的CML的最佳治疗策略.
- 讨论第三代技术知识的作用和未来的治疗方向.
主要方法:
- 现有文献的叙述性审查.
- 对T315I突变的临床数据的分析.
- 检查治疗选择和新兴策略.
主要成果:
- 该T315I突变赋予了对许多已批准的TKI的耐药性.
- 第三代TKI在克服T315I介导的阻力方面表现有前途.
- 鉴定T315I突变CML的有效疗法对于改善患者预后至关重要.
结论:
- 在CML管理中,T315I突变是一个主要障碍.
- 针对性疗法,特别是新一代的技术技能,对于耐药性CML至关重要.
- 对新型治疗策略的持续研究对于推进CML治疗至关重要.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K